NeoGenomics (NEO) is back on investor radars after recent trading showed sharp short term swings, with the stock down over the past week but up strongly over the past month and past 3 months.

Looking past the latest pullback, NeoGenomics has a 1 year total shareholder return of 50.07% despite a year to date share price decline of 10.80%. This suggests recent momentum has cooled after a strong rebound over the past quarter.

If the recent swings in NeoGenomics have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning 40 healthcare AI stocks

So with NeoGenomics shares swinging between short term weakness and a strong 1 year rebound, are you looking at an undervalued cancer testing specialist, or is the current price already reflecting expectations for future growth?

Most Popular Narrative: 30.3% Undervalued

With NeoGenomics stock last closing at $10.49 against a narrative fair value of $15.06, the widely followed view is that the market is discounting its long term earnings potential relative to projected oncology testing growth and margin improvement.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Want to see what sits behind that oncology growth story? The narrative leans on steady revenue expansion, a shift toward higher margin tests, and a richer earnings multiple than many peers. Curious how those moving parts combine to reach a fair value well above the current share price? The full breakdown joins the dots between growth, margins and valuation in a way the headline price alone cannot.

Result: Fair Value of $15.06 (UNDERVALUED)

However, the NeoGenomics story could shift quickly if competition in oncology diagnostics squeezes pricing, or if pharma related demand and nonclinical revenues remain weak and unpredictable.

Another View: NeoGenomics Stock Through a Sales Multiple Lens

The narrative model points to NeoGenomics being 30.3% undervalued, but its current P/S ratio of 1.8x tells a different story. That sits above both the estimated fair ratio of 1.3x and the peer and US Healthcare averages of 0.9x and 1.3x. This suggests less margin for error if growth or margins disappoint. Which signal should investors focus on when the story on profitability is still unresolved?

Next Steps

If the mixed signals around NeoGenomics have you unsure what to make of the story, it helps to look directly at the underlying risk flags and recent metrics so you can decide whether the current setup fits your approach, and that starts with understanding the 1 important warning sign

Looking for more investment ideas beyond NeoGenomics?

If NeoGenomics has sharpened your focus on where to put fresh capital next, broaden your watchlist with targeted stock ideas filtered for quality and specific strengths.

• Spot potential mispriced opportunities early by checking out screener containing 20 high quality undiscovered gems.
• Build resilience into your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (48 results).
• Prioritise capital preservation while still hunting for upside by scanning 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.